Alvotech Ordinary Shares ALVO 深 沪
已收盘 10-31 16:00:00 美东时间
7.65
-0.190
-2.42%
华盛通- 最 高7.81
- 今 开7.81
- 成交量 42.76万股
- 最 低 7.52
- 昨 收 7.84
- 总市值 23.94亿
- 52周最高 13.70
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 7.35
- 委 比 86.29%
- 总股本 3.13亿
- 历史最高 18.00
- 量 比 1.07
- 振 幅 3.70%
- 历史最低 5.20
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alvotech CCO Anil Okay steps down to become Adalvo CEO
Alvotech (NASDAQ:ALVO) on Wednesday announced changes to its global business development and commercial operations team. Anil Okay, Chief Commercial Officer, is stepping down to serve as Chief Executi...
10-22 20:13
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
Alvotech announced changes to its global business development and commercial operations team. Anil Okay is stepping down as Chief Commercial Officer to lead Adalvo. Trisha Durant has joined as Senior Vice President, Global Business Development and Commercial Operations, ex-North America. Harshika Sarbajna is now Senior Vice President Commercial, North America. Agne Pasko has been appointed Vice President Head of Business Development. Róbert Wessm...
10-22 09:00
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Morgan Stanley Upgrades Alvotech to Overweight, Announces $14 Price Target
Morgan Stanley analyst Thibault Boutherin upgrades Alvotech (NASDAQ:ALVO) from Equal-Weight to Overweight and announces $14 price target.
10-14 20:54
Alvotech’s AVT23 Biosimilar Gains EMA Acceptance
Alvotech ( ($ALVO) ) just unveiled an announcement. On October 6, 2025, Alvotec...
10-06 20:28
2. Advanz Pharma, Alvotech Move Closer To Launching Affordable Asthma And Allergy Treatment In Europe After EMA Filing Acceptance
Advanz Pharma Holdco Limited ("Advanz Pharma"), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ:ALVO), a global
10-06 16:45
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
Advanz Pharma and Alvotech announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair® (omalizumab). AVT23 aims to improve access to affordable biologic medicines for patients with severe asthma, chronic urticaria, and nasal polyps. Alvotech developed AVT23 in collaboration with Kashiv BioSciences LLC, and Advanz Pharma holds commercial rights in multiple regi...
10-06 08:40
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
Alvotech and Advanz Pharma announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion for Gobivaz®, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. The CHMP opinion recommends granting marketing authorization for Gobivaz® in the European Union and other countries. Alvotech is responsible for develo...
09-22 08:30
Alvotech's Commercialization Partner In Japan, Fuji Pharma, Receives Marketing Approval For Three New Biosimilars From Japanese Ministry Of Health, Labor And Welfare
Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma
09-19 19:47
